Cargando…
PGM1 and ENO1 Promote the Malignant Progression of Bladder Cancer via Comprehensive Analysis of the m6A Signature and Tumor Immune Infiltration
BACKGROUND: While N(6)-methyladenosine (m6A) modification of RNA and the tumor immune microenvironment both influence the progression of cancer, little attention has been paid to interactions between these two factors. Thus, we systematically explored potential biomarkers in the malignant progressio...
Autores principales: | Zhao, Jinglin, Huang, Shu, Tan, Dingji, Yang, Kaiqing, Chen, Mingyue, Jia, Xiongfei, Mao, Xiaoqin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894041/ https://www.ncbi.nlm.nih.gov/pubmed/35251177 http://dx.doi.org/10.1155/2022/8581805 |
Ejemplares similares
-
ORAL D-GALACTOSE SUPPLEMENTATION IN PGM1-CDG
por: Wong, Sunnie Yan-Wai, et al.
Publicado: (2017) -
Identification of ENO1 as a prognostic biomarker and molecular target among ENOs in bladder cancer
por: Huang, Zhengnan, et al.
Publicado: (2022) -
Galactose treatment of a PGM1 patient presenting with restrictive cardiomyopathy
por: Donoghue, Sarah E., et al.
Publicado: (2020) -
Successful heart transplantation in an infant with phosphoglucomutase 1 deficiency (PGM1‐CDG)
por: Altassan, Ruqaiah, et al.
Publicado: (2022) -
ENO1 and Cancer
por: Huang, Chen Kai, et al.
Publicado: (2022)